Authors' recommendations: Follicular lymphoma is the most common type of indolent (slow growing) non-Hodgkin lymphoma. Non-Hodgkin lymphoma is a type of blood cancer. People with follicular lymphoma often have large painless lymph nodes in the neck, armpits, stomach or groin. They may often suffer from fatigue, shortness of breath, night sweats and weight loss. Some patients may develop more aggressive forms of the disease. Ofatumumab is a new drug for the treatment of follicular lymphoma and is delivered straight into a vein. It sticks to cancer cells, making it easier for the body to destroy them. If licensed in the UK, ofatumumab with chemotherapy may be an option for patients whose disease has returned after initially responding to treatment.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/ofatumumab-arzerra-for-refractory-follicular-lymphoma-third-line-in-combination-with-bendamustine/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)